-
1
-
-
0037032835
-
The protein kinase complement of the human genome
-
Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
-
(2002)
Science
, vol.298
, pp. 1912-1934
-
-
Manning, G.1
Whyte, D.B.2
Martinez, R.3
Hunter, T.4
Sudarsanam, S.5
-
2
-
-
0032227735
-
The role of tyrosine phosphorylation in cell growth and disease
-
Hunter, T. The role of tyrosine phosphorylation in cell growth and disease. Harvey Lect. 94, 81-119 (1998).
-
(1998)
Harvey Lect.
, vol.94
, pp. 81-119
-
-
Hunter, T.1
-
3
-
-
0036527429
-
Protein kinases - The major drug targets of the twenty-first century?
-
Cohen, P. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309-315 (2002).
-
(2002)
Nat. Rev. Drug Discov.
, vol.1
, pp. 309-315
-
-
Cohen, P.1
-
4
-
-
4944261336
-
Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors
-
Mol, C.D., Fabbro, D. & Hosfield, D.J. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors. Curr. Opin. Drug Discov. Devel. 7, 639-648 (2004).
-
(2004)
Curr. Opin. Drug Discov. Devel.
, vol.7
, pp. 639-648
-
-
Mol, C.D.1
Fabbro, D.2
Hosfield, D.J.3
-
5
-
-
0034665713
-
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
-
Schindler, T. et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938-1942 (2000).
-
(2000)
Science
, vol.289
, pp. 1938-1942
-
-
Schindler, T.1
-
6
-
-
18344395134
-
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
-
Pargellis, C. et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9, 268-272 (2002).
-
(2002)
Nat. Struct. Biol.
, vol.9
, pp. 268-272
-
-
Pargellis, C.1
-
7
-
-
12144289677
-
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
-
Wan, P.T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004).
-
(2004)
Cell
, vol.116
, pp. 855-867
-
-
Wan, P.T.1
-
8
-
-
12144290647
-
Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis
-
Manley, P.W. et al. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim. Biophys. Acta 1697, 17-27 (2004).
-
(2004)
Biochim. Biophys. Acta
, vol.1697
, pp. 17-27
-
-
Manley, P.W.1
-
9
-
-
19944434344
-
Identification of novel p38α MAP kinase inhibitors using fragment-based lead generation
-
Gill, A.L. et al. Identification of novel p38α MAP kinase inhibitors using fragment-based lead generation. J. Med. Chem. 48, 414-426 (2005).
-
(2005)
J. Med. Chem.
, vol.48
, pp. 414-426
-
-
Gill, A.L.1
-
10
-
-
5444244504
-
Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase
-
Cumming, J.G. et al. Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett. 14, 5389-5394 (2004).
-
(2004)
Bioorg. Med. Chem. Lett.
, vol.14
, pp. 5389-5394
-
-
Cumming, J.G.1
-
11
-
-
31344438721
-
SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors
-
Heron, N.M. et al. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg. Med. Chem. Lett. 16, 1320-1323 (2006).
-
(2006)
Bioorg. Med. Chem. Lett.
, vol.16
, pp. 1320-1323
-
-
Heron, N.M.1
-
12
-
-
0033026444
-
Strategies toward the design of novel and selective protein tyrosine kinase inhibitors
-
Traxler, P. & Furet, P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther. 82, 195-206 (1999).
-
(1999)
Pharmacol. Ther.
, vol.82
, pp. 195-206
-
-
Traxler, P.1
Furet, P.2
-
13
-
-
32344437258
-
Discovery of novel and potent thiazoloquinazolines as selective Aurora a and B kinase inhibitors
-
Jung, F.H. et al. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J. Med. Chem. 49, 955-970 (2006).
-
(2006)
J. Med. Chem.
, vol.49
, pp. 955-970
-
-
Jung, F.H.1
-
14
-
-
24944543833
-
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors
-
Dai, Y. et al. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. J. Med. Chem. 48, 6066-6083 (2005).
-
(2005)
J. Med. Chem.
, vol.48
, pp. 6066-6083
-
-
Dai, Y.1
-
15
-
-
0032563315
-
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors
-
Gray, N.S. et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533-538 (1998).
-
(1998)
Science
, vol.281
, pp. 533-538
-
-
Gray, N.S.1
-
16
-
-
0033200390
-
Structural basis for selective inhibition of Src family kinases by PP1
-
Liu, Y. et al. Structural basis for selective inhibition of Src family kinases by PP1. Chem. Biol. 6, 671-678 (1999).
-
(1999)
Chem. Biol.
, vol.6
, pp. 671-678
-
-
Liu, Y.1
-
17
-
-
0032530336
-
Structural basis of inhibitor selectivity in MAP kinases
-
Wang, Z. et al. Structural basis of inhibitor selectivity in MAP kinases. Structure 6, 1117-1128 (1998).
-
(1998)
Structure
, vol.6
, pp. 1117-1128
-
-
Wang, Z.1
-
18
-
-
12644277392
-
The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase
-
Wilson, K.P. et al. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 4, 423-431 (1997).
-
(1997)
Chem. Biol.
, vol.4
, pp. 423-431
-
-
Wilson, K.P.1
-
19
-
-
0028582185
-
Crystal structure of the tyrosine kinase domain of the human insulin receptor
-
Hubbard, S.R., Wei, L., Ellis, L. & Hendrickson, W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372, 746-754 (1994).
-
(1994)
Nature
, vol.372
, pp. 746-754
-
-
Hubbard, S.R.1
Wei, L.2
Ellis, L.3
Hendrickson, W.A.4
-
20
-
-
0036682301
-
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)
-
Nagar, B. et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236-4243 (2002).
-
(2002)
Cancer Res.
, vol.62
, pp. 4236-4243
-
-
Nagar, B.1
-
21
-
-
0036769168
-
Imatinib: A selective tyrosine kinase inhibitor
-
Manley, P.W. et al. Imatinib: a selective tyrosine kinase inhibitor. Eur. J. Cancer 38 (suppl. 5), S19-S27 (2002).
-
(2002)
Eur. J. Cancer
, vol.38
, Issue.5 SUPPL.
-
-
Manley, P.W.1
-
22
-
-
0037019275
-
Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate
-
Regan, J. et al. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J. Med. Chem. 45, 2994-3008 (2002).
-
(2002)
J. Med. Chem.
, vol.45
, pp. 2994-3008
-
-
Regan, J.1
-
23
-
-
0036401042
-
Design and discovery of small molecules targeting raf-1 kinase
-
Lowinger, T.B., Riedl, B., Dumas, J. & Smith, R.A. Design and discovery of small molecules targeting raf-1 kinase. Curr. Pharm. Des. 8, 2269-2278 (2002).
-
(2002)
Curr. Pharm. Des.
, vol.8
, pp. 2269-2278
-
-
Lowinger, T.B.1
Riedl, B.2
Dumas, J.3
Smith, R.A.4
-
24
-
-
19944429284
-
A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase
-
Atwell, S. et al. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J. Biol. Chem. 279, 55827-55832 (2004).
-
(2004)
J. Biol. Chem.
, vol.279
, pp. 55827-55832
-
-
Atwell, S.1
-
25
-
-
4644289313
-
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
-
Wood, E.R. et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64, 6652-6659 (2004).
-
(2004)
Cancer Res.
, vol.64
, pp. 6652-6659
-
-
Wood, E.R.1
-
26
-
-
0034642482
-
Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase
-
Shewchuk, L. et al. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4- anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J. Med. Chem. 43, 133-138 (2000).
-
(2000)
J. Med. Chem.
, vol.43
, pp. 133-138
-
-
Shewchuk, L.1
-
27
-
-
85029168478
-
-
Preparation of pyrazolo[3,4-d]pyrimidine derivatives for treating diseases associated with inappropriate angiogenesis. World patent application WO2003029209 (2003)
-
Adams, J.L., Kasparec, J., Silva, D. & Yuan, C.C.K. Preparation of pyrazolo[3,4-d]pyrimidine derivatives for treating diseases associated with inappropriate angiogenesis. World patent application WO2003029209 (2003).
-
-
-
Adams, J.L.1
Kasparec, J.2
Silva, D.3
Yuan, C.C.K.4
-
28
-
-
20144375600
-
Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: Synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N′-(4-(4-quinolyloxy)phenyl)ureas
-
Kubo, K. et al. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N′-(4-(4-quinolyloxy)phenyl)ureas. J. Med. Chem. 48, 1359-1366 (2005).
-
(2005)
J. Med. Chem.
, vol.48
, pp. 1359-1366
-
-
Kubo, K.1
-
29
-
-
85029155343
-
-
Preparation of heteroaryl-substituted diarylureas as tyrosine kinase inhibitors. World patent application WO2005019192 (2005)
-
Hoelzemann, G. et al. Preparation of heteroaryl-substituted diarylureas as tyrosine kinase inhibitors. World patent application WO2005019192 (2005).
-
-
-
Hoelzemann, G.1
-
30
-
-
85029153574
-
-
Preparation of pyrimidopyrimidines as protein kinase inhibitors. World patent application WO2005011597 (2005)
-
Sim, T. et al. Preparation of pyrimidopyrimidines as protein kinase inhibitors. World patent application WO2005011597 (2005).
-
-
-
Sim, T.1
-
31
-
-
85029177746
-
-
Preparation of [1,6]naphthyridin-3-ones as protein kinase inhibitors. ç patent application WO2005034869 (2005)
-
Ding, Q. et al. Preparation of [1,6]naphthyridin-3-ones as protein kinase inhibitors. ç patent application WO2005034869 (2005).
-
-
-
Ding, Q.1
-
32
-
-
85029169583
-
-
Preparation of N-[3-(2-amino-7-oxo-7,8-dihydropteridin-6-yl)phenyl] benzamides as protein kinase inhibitors. World patent application WO2006002367 (2006)
-
Ren, P., Wang, X., Gray, N.S., Liu, Y. & Sim, T. Preparation of N-[3-(2-amino-7-oxo-7,8-dihydropteridin-6-yl)phenyl] benzamides as protein kinase inhibitors. World patent application WO2006002367 (2006).
-
-
-
Ren, P.1
Wang, X.2
Gray, N.S.3
Liu, Y.4
Sim, T.5
-
33
-
-
19744365702
-
A small molecule-kinase interaction map for clinical kinase inhibitors
-
Fabian, M.A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336 (2005).
-
(2005)
Nat. Biotechnol.
, vol.23
, pp. 329-336
-
-
Fabian, M.A.1
-
35
-
-
29144520253
-
Exploiting structural principles to design cyclin-dependent kinase inhibitors
-
Noble, M. et al. Exploiting structural principles to design cyclin-dependent kinase inhibitors. Biochim. Biophys. Acta 1754, 58-64 (2005).
-
(2005)
Biochim. Biophys. Acta
, vol.1754
, pp. 58-64
-
-
Noble, M.1
-
36
-
-
4644265514
-
The role of structure in kinase-targeted inhibitor design
-
Pratt, D.J., Endicott, J.A. & Noble, M.E. The role of structure in kinase-targeted inhibitor design. Curr. Opin. Drug Discov. Devel. 7, 428-436 (2004).
-
(2004)
Curr. Opin. Drug Discov. Devel.
, vol.7
, pp. 428-436
-
-
Pratt, D.J.1
Endicott, J.A.2
Noble, M.E.3
|